SNN
Smith & Nephew plcNYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 22, 11:56 AM
    • New guidelines from the World Health Organization (WHO) recommend the use of negative pressure wound therapy (NPWT) in adult patients on primarily closed surgical incisions in high-risk wounds as a way to reduce surgical site infection and the length of hospital stay.
    • The guidelines bode well for Smith & Nephew's (SNN -1.5%) single-use NPWT system called PICO, which has demonstrated its ability to reduce surgical site complications in orthopedic surgery in addition to a wide range of high-risk wounds.
    | Tue, Nov. 22, 11:56 AM | 1 Comment
  • Mon, Nov. 14, 3:50 PM
    • Anheuser-Busch (BUD -5.4%)
    • Infosys (INFY -3%)
    • National Grid (NGG -3.9%)
    • Smith & Nephew (SNN -1.5%)
    | Mon, Nov. 14, 3:50 PM | 6 Comments
  • Thu, Nov. 3, 7:58 AM
    • Smith & Nephew plc (NYSE:SNN): Q3 Revenue of $1.12B (+0.9% Y/Y)
    • Sports Medicine, Trauma & Other Revenue: $457M
    • Reconstruction Revenue: $351M
    • Advanced Wound Management Revenue: $311M
    • Press Release
    | Thu, Nov. 3, 7:58 AM
  • Wed, Oct. 5, 8:27 AM
    • Smith & Nephew plc (NYSE:SNN) had declared $0.25/ADS semi-annual dividend, -35.3% decrease from prior dividend of $0.38.
    • Payable Oct. 25; for shareholders of record Oct. 7; ex-div Oct. 5.
    | Wed, Oct. 5, 8:27 AM
  • Thu, Jul. 28, 5:20 AM
    • Smith & Nephew plc (NYSE:SNN): H1'16 EPS of $0.27
    • Revenue of $2.33B (+2.6% Y/Y)
    • Shares -4% PM.
    • Press Release
    | Thu, Jul. 28, 5:20 AM
  • Wed, May 18, 8:42 AM
    • Smith & Nephew plc (NYSE:SNN) has agreed to sell its gynecology unit to Medtronic plc (NYSE:MDT) for $350M. The deal is expected to reduce SNN's 2016 non-GAAP EPS by less that $0.01 and be neutral in 2017.
    • SNN intends to buyback $300M in shares following the transaction.
    | Wed, May 18, 8:42 AM | 1 Comment
  • Thu, May 5, 8:56 AM
    • Smith & Nephew (NYSE:SNN): Q1 Revenue of $1.14B (+3.6% Y/Y)
    • Shares -2.64% PM.
    | Thu, May 5, 8:56 AM | 1 Comment
  • Fri, Feb. 12, 7:38 AM
    • Gilead Sciences (NASDAQ:GILD) initiated with Outperform rating and $120 (37% upside) price target by Oppenheimer.
    • CareDx (NASDAQ:CDNA) initiated with Buy rating and $12 (137% upside) price target by Janney Capital.
    • Shire plc (NASDAQ:SHPG) initiated with Neutral rating by Guggenheim.
    • Ultragenyx Pharmaceutical (NASDAQ:RARE) initiated with Buy rating and $104 (95% upside) price target by H.C. Wainwright.
    • Depomed (NASDAQ:DEPO) initiated with Buy rating and $22 (38% upside) price target by UBS.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $40 (128% upside) price target by Bank of America.
    • Leerink restarts coverage on eight stocks: four Outperforms: Alexion Pharmaceuticals (NASDAQ:ALXN); Regeneron Pharmaceuticals (NASDAQ:REGN); Vertex Pharmaceuticals (NASDAQ:VRTX) and Gilead Sciences (GILD); four Market Performs: Celgene (NASDAQ:CELG); Biogen (NASDAQ:BIIB); Medivation (NASDAQ:MDVN) and Amgen (NASDAQ:AMGN).
    • TESARO (NASDAQ:TSRO) initiated with Buy rating by Lake Street.
    • AbbVie (NYSE:ABBV) initiated with Outperform rating by William Blair.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Buy with $38 (41% upside) price target by Cantor Fitzgerald.
    • Shire plc (SHPG) upgraded to Outperform with price target of $240 (59% upside) by RBC.
    • Amedisys (NASDAQ:AMED) upgraded to Outperform with $40 (15% upside) price target by Oppenheimer.
    • Smith & Nephew (NYSE:SNN) downgraded to Neutral from Buy by UBS. Price target lowered to 1,100p (4% upside) from 1,250p.
    • Quidel (NASDAQ:QDEL) downgraded to Hold from Buy by Canaccord. Price target lowered to $18 (18% upside) from $22.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) downgraded Neutral from Overweight by JP Morgan. Price target lowered to $5 (201% upside) from $16.
    | Fri, Feb. 12, 7:38 AM | 11 Comments
  • Thu, Feb. 4, 1:03 PM
    • Smith & Nephew (NYSE:SNN) declares semi-annual dividend of $0.38/ADS bringing total annual dividend to $0.616/ADS (+4% Y/Y).
    • The annual dividend of $0.616/ADS represents yield of 2.34% payable on May 11 to shareholders on record of April 22.
    | Thu, Feb. 4, 1:03 PM
  • Thu, Feb. 4, 10:49 AM
    • Smith & Nephew (SNN -1.7%) FY15 results: Revenues: $4,634M (+0.4%); R&D Expense: $222M (-5.5%); SG&A: $2,641M (+6.9%); Operating Income: $628M (-16.2%); Net Income: $410M (-18.2%); EPS: $0.46 (-17.9%); Non-GAAP EPS: $0.85 (+2.4%).
    • No guidance given.
    | Thu, Feb. 4, 10:49 AM
  • Thu, Feb. 4, 7:44 AM
    • Smith & Nephew (NYSE:SNN): FY15 EPS of $0.85
    • Revenue of $4.63B (+0.2% Y/Y)
    | Thu, Feb. 4, 7:44 AM
  • Mon, Feb. 1, 9:07 AM
    • In a regulatory filing, Smith & Nephew (NYSE:SNN) discloses that CEO Olivier Buhuon has been diagnosed with an undisclosed but highly treatable cancer. His treatment will begin later this month and continue into the fall. He will continue to be active in leading the company during this time but Chairman Roberto Quarta will step in if needed.
    • Mr. Buhuon will present the company's Q4 and full-year results on Thursday, as usual.
    | Mon, Feb. 1, 9:07 AM
  • Dec. 18, 2015, 10:31 AM
    • M&A rumors are active this morning with the latest being Stryker (SYK -1%) eyeing Smith & Nephew (SNN +3.5%).
    • Unsurprisingly, Merck (MRK -1.1%) continues to eye Relypsa (RLYP +0.9%).
    • Previously: Relypsa up 17% on rumored Merck interest (Dec. 4)
    • Update: Sources say the Stryker will pay ~$18B for SNN. A deal could be announced as early as next week.
    | Dec. 18, 2015, 10:31 AM | 23 Comments
  • Oct. 29, 2015, 9:13 AM
    | Oct. 29, 2015, 9:13 AM
  • Jul. 30, 2015, 9:07 AM
    • Smith & Nephew plc (NYSE:SNN): Q2 EPS of $0.39 in-line.
    • Revenue of $1.17B (+1.7% Y/Y) beats by $30M.
    | Jul. 30, 2015, 9:07 AM
  • Jun. 29, 2015, 3:30 PM
    • Becton, Dickinson (BDX +0.3%) upgraded to Buy from undefined with a $167 (18% upside) price target by UBS.
    • Community Health Systems (CYH -0.9%) upgraded to Buy from Neutral with an $83.90 (33% upside) price target by Mizuho Securities.
    • LifePoint Health (LPNT +2.8%) upgraded to Buy from Neutral with a $95.71 (11% upside) price target by Mizuho Securities.
    • UnitedHealth Group (UNH -1.3%) upgraded to Buy from Neutral with a $126 (3% upside) price target by Sterne Agee CRT.
    • Tenet Healthcare (THC -1.5%) upgraded to Outperform from Market Perform with a $64 (12% upside) price target by Wells Fargo.
    • Cepheid (CPHD -1.7%) raised to Buy from Hold with a $75 (25% upside) price target by Craig-Hallum.
    • Merge Healthcare (MRGE -0.1%) upgraded to Buy from Hold with a $5.75 (17% upside) price target by Topeka Capital.
    • Alere (ALR -0.2%) upgraded to Buy from Neutral with a $60 (15% upside) price target by Goldman Sachs.
    • Smith & Nephew (SNN -2.1%) upgraded to Buy from Neutral with a 1275p (16% upside) price target by UBS.
    • Aerie Pharmaceuticals (AERI -4.3%) upgraded to Buy from Hold with a $40 (135% upside) price target by Canaccord Genuity.
    | Jun. 29, 2015, 3:30 PM